Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Skye Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.537 -- 00:00:02.539 Good afternoon and thank you for standing by. 00:00:02.539 -- 00:00:05.262 My name is Abby and I will be your conference operator today. 00:00:05.262 -- 00:00:10.508 At this time, I would like to welcome everyone to the Sky Bioscience 2025 00:00:10.508 -- 00:00:14.172 fourth quarter financial results and business update call. 00:00:14.172 -- 00:00:18.336 All lines have been placed on mute to prevent any background noise. 00:00:18.336 -- 00:00:21.179 After the speaker's remarks, there will be a question and answer session. 00:00:21.179 -- 00:00:25.404 If you would like to ask a question during this time, simply press star followed by the 00:00:25.404 -- 00:00:29.822 number one on your telephone keypad. If you would like to withdraw your question, press 00:00:29.822 -- 00:00:32.065 star one a second time. 00:00:32.065 -- 00:00:36.169 Before we begin, please note that today's discussion includes forward-looking statements 00:00:36.169 -- 00:00:41.576 subject to risks and uncertainties described in Sky's SEC filings. 00:00:41.576 -- 00:00:44.399 Actual results may differ materially. 00:00:44.399 -- 00:00:48.864 Thank you. And I would now like to turn the conference over to Puneet Dhillon, Chief 00:00:48.864 -- 00:00:52.506 Executive Officer. You may begin. 00:00:52.588 -- 00:00:56.123 Good afternoon, everyone. Thank you for joining us. 00:00:56.123 -- 00:00:59.908 I'll start with what we've accomplished since our Q3 update. 00:00:59.908 -- 00:01:05.456 C-Beyond established a potential path for namazumab alongside existing incretin therapies 00:01:05.456 -- 00:01:10.863 with additive weight loss, encouraging durability and favorable tolerability. 00:01:10.863 -- 00:01:15.510 At the same time, we strengthened the plan around the signal w...